|
WO2008091770A1
(en)
*
|
2007-01-24 |
2008-07-31 |
Array Biopharma Inc. |
2-aminopyridine derivatives as glucokinase activators
|
|
US8362037B2
(en)
*
|
2007-03-23 |
2013-01-29 |
Array Biopharma, Inc. |
2-aminopyridine analogs as glucokinase activators
|
|
WO2009022171A1
(en)
*
|
2007-08-13 |
2009-02-19 |
Astrazeneca Ab |
Pyridinyiioxy pyridines as alk5 inhibitors
|
|
WO2009022179A2
(en)
*
|
2007-08-14 |
2009-02-19 |
Astrazeneca Ab |
Glucokinase activators in the treatment of osteoarthritis
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
AU2008305294B2
(en)
*
|
2007-09-21 |
2012-11-29 |
Array Biopharma Inc. |
Pyridin-2 -yl-amino-1, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
|
|
JP5567481B2
(ja)
*
|
2007-10-09 |
2014-08-06 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコキナーゼアクチベーターとして有用なピリジン誘導体
|
|
JP5693239B2
(ja)
|
2008-01-23 |
2015-04-01 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
４−ピリジノン化合物および癌についてのその使用
|
|
US7741327B2
(en)
|
2008-04-16 |
2010-06-22 |
Hoffmann-La Roche Inc. |
Pyrrolidinone glucokinase activators
|
|
MY159230A
(en)
|
2008-10-02 |
2016-12-30 |
Respivert Ltd |
P38 map kinase inhibitors
|
|
JPWO2010058846A1
(ja)
*
|
2008-11-21 |
2012-04-19 |
アステラス製薬株式会社 |
４，６−ジアミノニコチンアミド化合物
|
|
JP5670912B2
(ja)
|
2008-12-11 |
2015-02-18 |
レスピバート・リミテツド |
ｐ３８ＭＡＰキナーゼ阻害剤
|
|
GB0905955D0
(en)
|
2009-04-06 |
2009-05-20 |
Respivert Ltd |
Novel compounds
|
|
GB0921731D0
(en)
|
2009-12-11 |
2010-01-27 |
Respivert Ltd |
Theraputic uses
|
|
GB0921730D0
(en)
|
2009-12-11 |
2010-01-27 |
Respivert Ltd |
Method of treatment
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
CA2800498C
(en)
|
2010-03-31 |
2021-11-16 |
The Scripps Research Institute |
Reprogramming cells
|
|
GB201005589D0
(en)
|
2010-04-01 |
2010-05-19 |
Respivert Ltd |
Novel compounds
|
|
EP2556068B1
(en)
|
2010-04-08 |
2019-01-23 |
Respivert Limited |
P38 map kinase inhibitors
|
|
WO2011124923A2
(en)
|
2010-04-08 |
2011-10-13 |
Respivert Limited |
Novel compounds
|
|
US8178689B2
(en)
|
2010-06-17 |
2012-05-15 |
Hoffman-La Roche Inc. |
Tricyclic compounds
|
|
WO2011157827A1
(de)
|
2010-06-18 |
2011-12-22 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
KR20180099933A
(ko)
|
2010-11-19 |
2018-09-05 |
리간드 파마슈티칼스 인코포레이티드 |
복소환 아민 및 이의 용도
|
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
|
US8828995B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
|
EP2683699B1
(de)
|
2011-03-08 |
2015-06-24 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
EP2683705B1
(de)
|
2011-03-08 |
2015-04-22 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
WO2012120052A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
JPWO2012121314A1
(ja)
|
2011-03-09 |
2014-07-17 |
第一三共株式会社 |
ジピリジルアミン誘導体
|
|
CN102786517B
(zh)
*
|
2011-05-18 |
2017-06-06 |
中国医学科学院药物研究所 |
Gk和ppar双重激动活性的嘧啶噻唑胺类衍生物
|
|
JP5748210B2
(ja)
*
|
2011-05-26 |
2015-07-15 |
日本化薬株式会社 |
複素環化合物の製造方法
|
|
KR20180084153A
(ko)
*
|
2011-06-10 |
2018-07-24 |
메르크 파텐트 게엠베하 |
Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
|
|
US9133174B2
(en)
|
2011-09-05 |
2015-09-15 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing coumarin derivative
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP2760862B1
(en)
|
2011-09-27 |
2015-10-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
WO2013086397A1
(en)
*
|
2011-12-08 |
2013-06-13 |
Array Biopharma Inc. |
Urea compounds as gka activators
|
|
WO2013173672A1
(en)
|
2012-05-18 |
2013-11-21 |
Array Biopharma Inc. |
Method for the preparation of thiadiazoles
|
|
CN104781251B
(zh)
*
|
2012-11-08 |
2016-12-14 |
百时美施贵宝公司 |
可作为激酶调节剂的经双环杂环取代的吡啶基化合物
|
|
WO2014076484A1
(en)
|
2012-11-16 |
2014-05-22 |
Respivert Limited |
Kinase inhibitors
|
|
WO2014159938A1
(en)
*
|
2013-03-13 |
2014-10-02 |
The Broad Institute, Inc. |
Substituted aminothiazoles for the treatment of tuberculosis
|
|
WO2016001341A1
(en)
*
|
2014-07-03 |
2016-01-07 |
F. Hoffmann-La Roche Ag |
Sulfonylaminopyridine compounds, compositions and methods of use
|
|
CN106749002A
(zh)
*
|
2015-02-12 |
2017-05-31 |
佛山市赛维斯医药科技有限公司 |
一种含硝基喹啉结构的葡萄糖激酶活化剂及其用途
|
|
EP3259256B1
(en)
*
|
2015-02-17 |
2022-03-09 |
Beijing Erai Therapeutics Co., Ltd. |
Compounds and methods for inducing browning of white adipose tissue
|
|
US10807983B2
(en)
|
2015-03-16 |
2020-10-20 |
Ligand Pharmaceuticals, Inc. |
Imidazo-fused heterocycles and uses thereof
|
|
AU2016245434B2
(en)
*
|
2015-04-07 |
2020-10-29 |
Ela Pharma Ltd |
Compositions for treating and/or preventing cell or tissue necrosis specifically targeting Cathepsin C and/or CELA1 and/or CELA3A and/or structurally related enzymes thereto
|
|
CN107848932B
(zh)
*
|
2015-06-11 |
2025-09-02 |
解向群 |
p62-ZZ化学抑制剂
|
|
WO2017102091A1
(en)
|
2015-12-18 |
2017-06-22 |
Bayer Pharma Aktiengesellschaft |
Heteroarylbenzimidazole compounds
|
|
WO2017207534A1
(en)
|
2016-06-03 |
2017-12-07 |
Bayer Pharma Aktiengesellschaft |
Substituted heteroarylbenzimidazole compounds
|
|
EP3848370B1
(en)
*
|
2016-10-14 |
2025-05-07 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors and uses thereof
|
|
US12030875B2
(en)
|
2018-09-07 |
2024-07-09 |
PIC Therapeutics, Inc. |
EIF4E inhibitors and uses thereof
|
|
EP3990445A4
(en)
*
|
2019-06-25 |
2023-07-05 |
InventisBio Co., Ltd. |
HETEROCYCLIC COMPOUNDS, METHODS FOR THEIR PREPARATION AND THEIR METHODS OF USE
|
|
CN110898049B
(zh)
*
|
2019-11-29 |
2021-09-14 |
华中师范大学 |
二硫化合物在制备药物中的应用、fbp酶抑制剂及用于预防和/或治疗糖尿病的药剂
|
|
AU2021230289A1
(en)
|
2020-03-03 |
2022-09-29 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
|
WO2022147694A1
(en)
*
|
2021-01-06 |
2022-07-14 |
Beijing Erai Therapeutics Co., Ltd. |
Aminoheteroaryl compounds and uses thereof
|
|
US12157732B2
(en)
|
2021-08-25 |
2024-12-03 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
|
JP2024534127A
(ja)
|
2021-08-25 |
2024-09-18 |
ピク セラピューティクス， インコーポレイテッド |
ｅＩＦ４Ｅ阻害剤及びその使用
|